NICE recommends new treatment for rare blood disorder
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
-
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
-
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
-
NICE launches ambitious strategy to provide quicker access to new treatments and innovations
NICE will transform key elements of its approach to ensure efficiency and speed while maintaining robust, trusted methods.
